Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BioCryst’s Oral Therapy For HAE Attacks On Track With Exploratory Phase II Success

Sep 04 2018

• By Joseph Haas

Medic staff at work in the laboratory. Background

Related Content

With Takhzyro Approval, Shire Could Reclaim HAE Prophylaxis Market From CSL Behring

Aug 24 2018

CSL Behring Nears Market With Easier-To-Administer HAE Prophylactic

Mar 23 2017

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

Jul 13 2018

Better Together: BioCryst, Idera Merge To Improve Rare Disease Position

Jan 22 2018

Related Companies

BioCryst Pharmaceuticals, Inc.

Takeda Pharmaceutical Co. Ltd.

CSL Limited

Additional Topics

Clinical Trials Rare Diseases Research & Development Business Strategies BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window